Heart‑Rate Monitoring and Discontinuation Criteria for Psychostimulants in Adolescents

Pre‑Treatment Cardiac Screening

• Obtain baseline vital signs (resting heart rate and blood pressure) before starting a stimulant to establish each adolescent’s individual norm. American Academy of Child and Adolescent Psychiatry recommends this as a mandatory step. 1
• Conduct a detailed cardiovascular history that includes personal episodes of syncope, palpitations, or reduced exercise tolerance, and a family history of sudden death before age 35 (including unexplained motor‑vehicle accidents, drownings, or SIDS). Canadian Cardiovascular Society emphasizes the importance of this history. 2
• Perform a focused physical examination to identify pathologic cardiac murmurs and absent or delayed femoral pulses, which may signal underlying structural disease. Canadian Cardiovascular Society guidance. 2

Monitoring Schedule During Treatment

• Titration phase: Measure heart rate and blood pressure at every dose adjustment. American Academy of Child and Adolescent Psychiatry. 3
• Maintenance phase: Perform annual vital‑sign checks during routine physical examinations for children and adolescents. American Academy of Child and Adolescent Psychiatry. 1
• Symptom‑driven assessment: If any cardiovascular symptoms appear, reassess immediately with vital‑sign measurement and further cardiac work‑up. Canadian Cardiovascular Society. 2

Thresholds for Clinical Concern

Absolute Heart‑Rate Values

• Persistent resting tachycardia > 100 bpm in an adolescent on stimulant therapy, especially when accompanied by other concerning signs, should trigger clinical attention. American Academy of Child and Adolescent Psychiatry. 1

Relative Increases from Baseline

• An increase of > 20–25 bpm from the individual baseline heart rate constitutes a high‑concern situation and warrants closer monitoring or intervention. (Guideline consensus; strength not explicitly graded).

Symptom‑Based Red Flags (Immediate Discontinuation)

• Exertional chest pain, unexplained syncope or near‑syncope, palpitations triggered by exercise/startle/fright, new‑onset reduced exercise tolerance, or severe shortness of breath with activity. Canadian Cardiovascular Society recommends immediate stimulant cessation and urgent cardiac evaluation. 2

Management of Elevated Heart Rate

Low‑ to Moderate‑Concern Elevations (No Symptoms)

• Reduce the stimulant dose by 25–50 %. American Academy of Child and Adolescent Psychiatry. 1
• Consider switching to an alternative stimulant formulation (different delivery system or medication class). American Academy of Child and Adolescent Psychiatry. 1
• If cardiovascular effects remain problematic, evaluate non‑stimulant ADHD therapies. American Academy of Child and Adolescent Psychiatry. 4

High‑Concern Elevations or Symptomatic Presentations

• Immediately discontinue the stimulant. American Academy of Child and Adolescent Psychiatry. 4
• Obtain an electrocardiogram and echocardiogram to assess for arrhythmia or structural disease. (Standard clinical practice; evidence level not specified).
• Refer the adolescent to pediatric cardiology for specialist evaluation. American Academy of Child and Adolescent Psychiatry. 1
• Do not restart the stimulant until formal cardiac clearance is obtained. American Academy of Child and Adolescent Psychiatry. 1

Serious Cardiovascular Risk Context

• The observed rate of sudden death among youths receiving ADHD medications is 0.2–0.5 per 100,000 patient‑years, which is comparable to the background rate in the general pediatric population. Canadian Cardiovascular Society. 2
• A family history of sudden unexplained death in young relatives may indicate an inherited arrhythmia syndrome and should be actively investigated rather than dismissed. Canadian Cardiovascular Society. 2

Blood Monitoring Recommendations for Lisdexamfetamine (Elvanse)

Routine Laboratory Monitoring

• The American Academy of Child and Adolescent Psychiatry states that routine blood work, including liver function tests, is not required for patients receiving lisdexamfetamine because the drug does not carry the hepatotoxicity risk seen with older stimulants such as pemoline. 5

Cardiovascular Monitoring Requirements

Baseline Assessment

• Prior to initiating lisdexamfetamine, clinicians should obtain baseline vital signs (resting heart rate and blood pressure) and conduct a detailed cardiovascular history and focused physical examination to identify any pre‑existing cardiac concerns. 5

Ongoing Monitoring During Treatment

• Titration phase: Heart rate and blood pressure should be measured at every dose adjustment.
• Maintenance phase: Annual vital‑sign checks are recommended during routine physical examinations.
• Symptom‑driven assessments: Immediate re‑evaluation of vital signs is required if any cardiovascular symptoms develop. All three points are endorsed by the American Academy of Child and Adolescent Psychiatry. 5

Clinical Thresholds for Concern

• Persistent resting tachycardia exceeding 100 bpm warrants clinical attention.
• An increase of 20–25 bpm above the individual’s baseline heart rate is considered a high‑concern situation. 5

Immediate Discontinuation (Red‑Flag Symptoms)

• Exertional chest pain, unexplained syncope or near‑syncope, palpitations triggered by exercise/startle, new‑onset reduced exercise tolerance, and severe shortness of breath with activity all constitute red‑flag symptoms that require immediate discontinuation of lisdexamfetamine and further cardiac evaluation. 5

Safety Profile Compared with Pemoline

• Lisdexamfetamine is a prodrug enzymatically converted to d‑amphetamine primarily by red blood cells, and it does not exhibit the hepatotoxicity that necessitated bi‑weekly ALT monitoring for pemoline. 5
• Long‑term studies demonstrate that lisdexamfetamine’s safety profile is consistent with other long‑acting stimulants, with most adverse events being mild to moderate and not requiring laboratory monitoring. 5

Hepatic Risk of Pemoline (Contrast)

• Pemoline required bi‑weekly liver‑function monitoring because it was associated with 13 cases of severe hepatic failure, of which 11 resulted in death or liver transplantation; this risk does not apply to lisdexamfetamine. 5

Management of Serious Cardiovascular Events

• If serious cardiovascular symptoms occur while on lisdexamfetamine, the guideline advises obtaining an electrocardiogram, echocardiogram, and cardiology referral before considering medication restart. 5